Notice of Allowance for Canada patent

RNS Number : 3795F

Eden Research plc

24 April 2014

 



Eden Research Plc

("Eden" or "Company")

Notice of Allowance for Canada patent

Eden Research plc (AIM: EDEN), the AIM listed natural micro-encapsulation company, announces that the Canadian Intellectual Property Office has issued a Notice of Allowance for its platform encapsulation technology.

The patent covers the Company's core technology, specifically "compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them."

The patent is owned outright by Eden and is already granted in Europe, New Zealand, Australia, China, Mexico, Singapore, the Philippines, South Africa and across a number of designated African states covered by the African Regional Intellectual Property Organisation (ARIPO). Formal patent grant will provide the security of full patent protection to existing and prospective licensees in Canada.

Clive Newitt, Managing Director of Eden comments: "We are delighted to announce this Notice of Allowance which further strengthens our intellectual property portfolio. Following on from the first commercial launch of products using our IP it is essential that we continue to increase our world-wide patent protect as more products move into commercialisation."

Eden Research plc	www.edenresearch.com
Clive Newitt, Managing Director	Tel: [phone]
Alex Abrey, Chief Financial Officer
W H Ireland Limited	Tel: [phone]
John Wakefield
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]

Notes:

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals. In May 2013 Eden received approval from the European Commission for the use of the three active substances in its lead agrichemical product 3AEY. 3AEY is an effective, naturally derived product against Botrytis. The Company is now in the process of seeking product approval for plant protection products using these three active substances.

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships. In April 2014 Eden announced the first commercial launch of products using Eden's intellectual property and expertise in encapsulation - pet odour neutralising products developed by TerpeneTech Ltd.

The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit www.edenresearch.com 

 

END

 

 

MSCLFFILSEIVFIS